

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT**

### **NMPA APPROVAL FOR REGISTRATION APPLICATION OF YonFlow® FLOW DIVERTING STENT**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that YonFlow® Flow Diverting Stent received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局) (the “**NMPA**”) for its registration application.

YonFlow® Flow Diverting Stent, developed by Jiangsu NowYon Medical Limited (“**NowYon Medical**”), is the first flow diverting stent system in the globe that can be retrieved after its complete release, which allows users to have precise control over the device during procedures. Meanwhile, the product’s cobalt-chrome alloy material provides stronger radial support and good vessel wall apposition.

Reference is made to the announcement of the Company dated August 28, 2024. The Group entered into an exclusive distribution agreement with NowYon Medical on August 16, 2024 for selling and distributing of the YonFlow® Flow Diverting Stent in the territory of the Greater China.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET THE YonFlow® FLOW DIVERTING STENT SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, April 9, 2025

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. WaiMing YIP and Mr. Huacheng WEI as independent non-executive Directors.*